E. coli Vaccine Program

About Baxiva

Baxiva is a private, pre-clinical stage biotech startup based in Zug, Switzerland, focused on innovative vaccine development. The company leverages a proprietary platform that chemically conjugates bacterial polysaccharides to virus-like particles (VLPs) to create highly immunogenic, multivalent vaccines against Gram-negative bacteria. Its primary target is E. coli, the leading cause of antibiotic-resistant infections, addressing a critical unmet need in global health. Baxiva is currently pre-revenue and in the early stages of advancing its lead candidate toward clinical development.

Therapeutic Areas